Clinical Trials Browser

Phase 1 × Specimen Handling × CNS × Clear all

NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Phase 1 Recruiting

Brain Neoplasms

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Phase 1 Recruiting

Astrocytoma

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Phase 1 Active not recruiting

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1 Suspended

Neuroblastoma, Osteosarcoma

NCT06860594 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Phase 1 Suspended

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 1 Not yet recruiting

Glioblastoma, Gliosarcoma

NCT06964737 2026-05-08

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Phase 1 Recruiting

Glioma

NCT07544992 2026-05-06

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Phase 1 Recruiting

Astrocytoma, Glioblastoma

NCT06410248 2026-05-01

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Phase 1 Recruiting

Glioblastoma

NCT05030298 2026-04-22

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Phase 1 Recruiting

Glioma

NCT07089641 2026-04-07

ERAS801-SARG

Phase 1 Recruiting

Astrocytoma

NCT05789394 2026-04-02

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Phase 1 Recruiting

Astrocytoma, Glioblastoma

NCT04197934 2026-03-30

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Phase 1 Active not recruiting

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Lung Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Phase 1 Completed

12 enrolled 12 charts

Neuroblastoma, Osteosarcoma

NCT03107780 2025-11-13

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Phase 1 Terminated

Glioblastoma, Gliosarcoma

NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Phase 1 Withdrawn

Central Nervous System Neoplasms

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase 1 Withdrawn

CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT05388877 2025-08-19

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Phase 1 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

Phase 1 Recruiting

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT06815029 2025-06-26

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Phase 1 Recruiting

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT03598244 2025-04-20

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Phase 1 Active not recruiting

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma, Central Nervous System Neoplasms

NCT02700230 2024-09-27

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

Phase 1 Completed

Neurofibromatosis 1, Neurofibrosarcoma

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

Phase 1 Withdrawn

Glioblastoma, Glioma

NCT06137651 2024-04-01

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis